RetaRick_CA said:MounjBrad said: ...regarding the discontinuation data for cost and coverage...
This is where I part company with the consensus forming above. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.
MounjBrad said:The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…
Insurance update relevant to cost and coverage: I just got my prior auth approved through UnitedHealthcare after 1 attempts.
What finally worked: a letter from my endocrinologist documenting BMI history (>3 years), failed diet attempts, comorbidities (PCOS + insulin resistance), and referencing the SURMOUNT trial data.
If your PA keeps getting denied, don't give up. Request a peer-to-peer review between your doctor and the insurance medical director. That's what finally broke through for me.
LabKate said:The affordability discussion here usually stops at individual tactics.
Telehealth prescriber review for cost and coverage: I've used 2 different telehealth platforms to get my GLP-1 prescription. Comparison:
| Feature | Platform A | Platform B | Platform C |
|---|---|---|---|
| Initial Consult | $51 | $91 | $0 |
| Monthly Follow-up | $41 | Included | $51 |
| Prescription Speed | Same day | 24-48 hours | Same day |
| Lab Monitoring | Required | Optional | Required |
I settled on the one that required labs — it shows they care about safety, not just prescribing volume.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFollowing on from emma_london — and this may be the naive question:
What did you change at the same time, and can you separate the two now?
OP back with an update, since a thread like this is useless without one.
Update: approved on the third attempt after a peer-to-peer. Nothing about my case changed; only who was doing the talking.